H7N9 T-cell Epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 9, 2015, Pages 2241-2252

  Liu, Rui ^a   Moise, Leonard ^a,b   Tassone, Ryan ^a   Gutierrez, Andres H ^a   Terry, Frances E ^b   Sangare, Kotou ^c   Ardito, Matthew T ^b   Martin, William D ^b   De Groot, Anne S ^a,b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b EpiVax Inc   (United States)

^c UNIVERSITY OF BAMAKO   (Mali)

Author keywords

Cross conservation; H7N9 influenza; Immune evasion; Immunoinformatics; JanusMatrix; Regulatory T cells (Tregs); Tolerance; Vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; INFLUENZA VACCINE;

ARTICLE; BINDING ASSAY; BYSTANDER EFFECT; CELL ISOLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENOME ANALYSIS; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFLUENZA A VIRUS (H7N9); NORMAL HUMAN; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REGULATORY T LYMPHOCYTE; SEROCONVERSION; CELL CULTURE; GENETICS; IMMUNOLOGY; SEQUENCE HOMOLOGY;

CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNE TOLERANCE; INFLUENZA A VIRUS, H7N9 SUBTYPE; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES, REGULATORY;

EID: 84951568573     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1052197     Document Type: Article

References (54)

1. Cumulative number of confirmed human death cases of pandemic influenza A/(H1N1) reported to WHO. Geneva, SWITZERLAND. 2010.
2. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12:687-95; PMID:22738893; http://dx.doi.org/10.1016/S1473-3099(12)70121-4
3. Katz J, Hancock K, Veguilla V, Zhong W, Lu XH, Sun H, Butler E, Dong L, Liu F, Li ZN, et al. Serum crossreactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:521-24; PMID:19478718
4. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52; PMID:19745214; http://dx.doi.org/10.1056/NEJMoa0906453
5. Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, Wittman V, Warren WL, Drake DR 3rd. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4 (C) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011; 29:3299-309; PMID:21349362; http://dx.doi.org/10.1016/j.vaccine.2011.02.019
6. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97; PMID:23577628; http://dx.doi.org/10.1056/NEJMoa1304459
7. NIH begins testing H7N9 avian influenza vaccine candidate, possible role for adjuvants to be examined. 2013; (Press Release, National Institutes of Health, Bethesda, Maryland). http://www.nih.gov/news/health/sep2013/niaid-18.htm
8. Novartis announces positive clinical trial results for novel H7N9 vaccine. Media Release Novartise 2013; http://www.novartis.com/newsroom/media-releases/en/2013/1743124.shtml
9. Fries LF, Smith GE, Glenn GM. A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine. N Engl J Med 2013; 369:2564-6; PMID:24224560; http://dx.doi.org/10.1056/NEJMc1313186
10. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, Talbot HK, Ohmit SE, Coleman LA, Lofthus G, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011; 6: e23085; PMID:21857999
11. Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 14:1409-19; http://dx.doi.org/10.1001/jama.2014.12854
12. Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H, Gao X, Teng Z, Li J, Hu J, et al. Human antibody responses to avian influenza A (H7N9) virus. Emerg Infect Dis 2013; 20:192-200; http://dx.doi.org/10.3201/eid2002.131094
13. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97; PMID:19368768; http://dx.doi.org/10.1016/j.vaccine.2009.01.116
14. Couch RB, Patel SM, Wade-Bowers CL, Niño D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012; 7: e49704; PMID:23239968; http://dx.doi.org/10.1371/journal.pone.0049704
15. Meijer A, Bosman A, van de Kamp EE, Wilbrink B, Du Ry van Beest Holle M, Koopmans M. Measurement of antibodies to avian influenza virus A (H7N7) in humans by hemagglutination inhibition test. J Virol Methods 2006; 132:113-20; PMID:16271401; http://dx.doi.org/10.1016/j.jviromet.2005.10.001
16. Leddon SA, Sant A. The peptide specificity of the endogenous T follicular helper cell repertoire generated after protein immunization. PLoS One 2012; 7: e46952; PMID:23077537; http://dx.doi.org/10.1371/journal.pone.0046952
17. Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4C T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A (H1N1) virus subtype H1N1 vaccine. J Infect Dis 2013; 207:297-305; PMID:23148285; http://dx.doi.org/10.1093/infdis/jis684
18. De Groot AS, Ardito M, Terry F, Levitz L, Ross T, Moise L, Martin W. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother 2013; 9:950-6; PMID:23807079; http://dx.doi.org/10.4161/hv.24939
19. He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics 2014; 15:S1; PMID:25104221; http://dx.doi.org/10.1186/1471-2105-15-S4-S1
20. Vider-Shalit T, Sarid R, Maman K, Tsaban L, Levi R, Louzoun Y. Viruses selectively mutate their CD8C Tcell epitopes—a large-scale immunomic analysis. Bioinformatics 2009; 25:i39-i44; PMID:19478014; http://dx.doi.org/10.1093/bioinformatics/btp221
21. Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, et al. Analysis of the Evolutionary Forces in an Immunodominant CD8 Epitope in Hepatitis C Virus at a Population Level. J Virol 2008; 82:3438-51; PMID:18216107; http://dx.doi.org/10.1128/JVI.01700-07
22. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein MB, Losikoff PT, Martin WD, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013; 9:1577-86; PMID:23584251; http://dx.doi.org/10.4161/hv.24615
23. Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C, De Groot AS, et al. HCV Epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. J Hepatol 2015; 62 (1):48-55.
24. Moise L, Liu R, Gutierrez AH, Tassone R, Bailey-Kellogg C, Martin WD, De Groot A. Immune Camouflage: Relevance to Vaccine Design and Human Immunology. Hum Vaccin. Immunother 2014; 1: e36134.
25. De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. Hum. Vaccin Immunother 2014; 10:256-62; http://dx.doi.org/10.4161/hv.28135
26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13:2498-504; PMID:14597658; http://dx.doi.org/10.1101/gr.1239303
27. Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum Vaccin Immunother 2013; 9:1598-1607; PMID:23846304; http://dx.doi.org/10.4161/hv.25598
28. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189-201; PMID:19269256; http://dx.doi.org/10.1016/j.clim.2009.01.009
29. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Jillian B, Gail D, Wilson H, Connie L, Diane W, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13; PMID:19745216; http://dx.doi.org/10.1056/NEJMoa0907413
30. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induced cross-protective immunity agasint A(H1N1)pandemic influenza virus in a ferret model. J Infect Dis 2010; 202:1011-20; PMID:20715930; http://dx.doi.org/10.1086/656188
31. Wang SM, Tsai MH, Lei HY, Wang JR, Liu CC. The regulatory T cells in anti-influenza antibody response post influenza vaccination. Hum Vaccin Immunother 2012; 8:1243-1249; PMID:22894960; http://dx.doi.org/10.4161/hv.21117
32. Cousens L, De Groot AS, Najafian N, Martin WD. Tregitopes: an immunomodulation powerhouse. Hum Immunol 2014; 75:1139-46; PMID:25454619; http://dx.doi.org/10.1016/j.humimm.2014.10.012
33. De Groot AS, Terry F, Cousens L, Martin W. Beyond Humanization and De-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Rev Clin Pharmacol 2013; 6:651-62; PMID:24164613; http://dx.doi.org/10.1586/17512433.2013.835698
34. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol 2013; 149:534-55; PMID:24263283; http://dx.doi.org/10.1016/j.clim.2013.09.006
35. Background and summary of human infection with avian influenza A (H7N9) virus – as of 31 January 2014. World Health Organization, Geneva, Switzerland. 2014; (http://www.who.int/influenza/human_animal_interface/latest_update_h7n9/en/)
36. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A (H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013; 18:20453; PMID:23594575
37. Gao HN, Yao HP, Liang WF, Wu XX, Wu HB, Wu NP, Yang SG, Zhang Q, Su KK, Guo J, et al. Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A (H7N9) virus in Zhejiang, China. Int J Infect Dis 2014; 29C:254-8; http://dx.doi.org/10.1016/j.ijid.2014.10.029
38. Kucharski A, Mills H, Pinsent A, Fraser C, Van Kerkhove M, Donnelly CA, Riley S. Distinguishing between reservoir exposure and human-to-human transmission for emerging pathogens using case onset data. PLoS Curr 2014; 6: pii: ecurrents.outbreaks.e1473d9bfc99d080ca242139a06c455f; PMID:24619563
39. Patarroyo ME, Cifuentes G, Salazar LM, Espejo F, Alba MP, Bermudez A. Based on HLA-DR beta1* allele binding specificities, striking differences in distance and TCR Contacting Residue Orientation can be observed in modified protection-inducing malarial synthetic peptides. Curr Med Chem 2005; 12:2849-65; PMID:16305475; http://dx.doi.org/10.2174/092986705774454733
40. Clute SC, Watkin LB, Cornberg M, Naumov YN, Sullivan JL, Luzuriaga K, Welsh RM, Selin LK. Crossreactive influenza virus-specific CD8C T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest 2005; 115: 3602-12; PMID:16308574; http://dx.doi.org/10.1172/JCI25078
41. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev 2010; 235:244-66; PMID:20536568
42. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virusspecific CD4 (C) memory-phenotype T cells are abundant in unexposed adults. Immunity 2013; 38:373-83; PMID:23395677; http://dx.doi.org/10.1016/j.immuni.2012.10.021
43. Calis JJ, de Boer RJ, Keşmir C. Degenerate T-cell recognition of peptides on MHC molecules creates large holes in the T-cell repertoire. PLoS Comput Biol 2012; 8:e1002412; PMID:22396638; http://dx.doi.org/10.1371/journal.pcbi.1002412
44. Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, Huang JC, Riadi G, Mallal S, Jojic N. Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol 2011; 85:1310-21; PMID:21084470; http://dx.doi.org/10.1128/JVI.01966-10
45. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 2010; 137:5-14; PMID:20708973; http://dx.doi.org/10.1016/j.clim.2010.06.018
46. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998; 160:322-7; PMID:9551987
47. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009; 27:6512-21; PMID:19729082; http://dx.doi.org/10.1016/j.vaccine.2009.08.053
48. The UniProt Consortium. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 2012; 40:D71-5; PMID:22102590; http://dx.doi.org/10.1093/nar/gkr981
49. Yang J, James E, Gates TJ, DeLong JH, LaFond RE, Malhotra U, Kwok WW. CD4C T cells recognize unique and conserved 2009 H1N1 influenza hemagglutinin epitopes after natural infection and vaccination. Int Immunol 2013; 25:447-57; PMID:23524391; http://dx.doi.org/10.1093/intimm/dxt005
50. Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4C T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 2005; 169:31-8; PMID:16150497; http://dx.doi.org/10.1016/j.jneuroim.2005.07.014
51. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4C T cells directed against H5N1 influenza virus. J Immunol 2008; 180:1758-68; PMID:18209073; http://dx.doi.org/10.4049/jimmunol.180.3.1758
52. Sun J, Li R, Guo J, Jia Y, Sun X, Liu Y, Li Y, Huang F, Lu L, Li Z. Superior molecularly altered influenza virus hemagglutinin peptide 308-317 inhibits collagen-induced arthritis by inducing CD4C Treg cell expansion. Arthritis Rheum 2012; 64:2158-68; PMID:22231228; http://dx.doi.org/10.1002/art.34372
53. Reijonen H, Kwok WW: Use of HLA class II tetramers in tracking antigen-specific T cells and map-ping Tcell epitopes. Methods 2003, 29:282-288; PMID:12725793
54. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73; PMID:9531296